OssDsign (OSSD) Hisse Özeti
OssDsign AB (publ) İsveç, Almanya, Amerika Birleşik Devletleri, Birleşik Krallık, Avrupa'nın geri kalanı ve uluslararası alanda kemik rejenerasyonu için implantlar ve malzeme teknolojisi tasarlar, üretir ve satar. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
OSSD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
OssDsign AB (publ) Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | SEK 4.14 |
| 52 Haftanın En Yüksek Seviyesi | SEK 16.72 |
| 52 Haftanın En Düşük Seviyesi | SEK 3.34 |
| Beta | 0.64 |
| 1 Aylık Değişim | 1.10% |
| 3 Aylık Değişim | -31.11% |
| 1 Yıllık Değişim | -67.81% |
| 3 Yıllık Değişim | -16.53% |
| 5 Yıllık Değişim | -50.95% |
| Halka arzdan bu yana değişim | -82.00% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 18
OSSD: Refined Forecast Assumptions And Q1 2026 Guidance Support Upside Potential
Analysts have kept their OssDsign price target steady at SEK5.10, with only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E, which feed into an unchanged fair value view. What’s in the News for OssDsign OssDsign issued earnings guidance for the first quarter of 2026, indicating an expected loss before interest and taxes in a range of SEK 12.0 million to SEK 14.0 million.Anlatı Güncellemesi • Jun 04
OSSD: Refined Forecast Assumptions Will Support Future Upside Potential
Analysts have maintained their SEK fair value estimate for OssDsign while updating inputs such as revenue growth, profit margin, discount rate and a lower future P/E assumption. Together, these changes support a refined price target framework without altering the headline SEK figure.Recent updates
Anlatı Güncellemesi • Jun 18
OSSD: Refined Forecast Assumptions And Q1 2026 Guidance Support Upside Potential
Analysts have kept their OssDsign price target steady at SEK5.10, with only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E, which feed into an unchanged fair value view. What’s in the News for OssDsign OssDsign issued earnings guidance for the first quarter of 2026, indicating an expected loss before interest and taxes in a range of SEK 12.0 million to SEK 14.0 million.Anlatı Güncellemesi • Jun 04
OSSD: Refined Forecast Assumptions Will Support Future Upside Potential
Analysts have maintained their SEK fair value estimate for OssDsign while updating inputs such as revenue growth, profit margin, discount rate and a lower future P/E assumption. Together, these changes support a refined price target framework without altering the headline SEK figure.Anlatı Güncellemesi • May 03
OSSD: Higher Long Term Margins And Moderate P/E Will Support Future Upside
Analysts have revised their price target for OssDsign to SEK 5.1 from SEK 13.5. The change reflects updated assumptions around growth, profitability and a more moderate future P/E multiple. What's in the News OssDsign issued earnings guidance for the first quarter of 2026, indicating a loss before interest and taxes in the range of SEK 12.0 million to SEK 14.0 million, with only marginal exchange rate impact (Key Developments).
Anlatı Güncellemesi • Apr 18
OSSD: Stable Loss Outlook And Assumptions Will Support Future Multiple Re Rating
Analysts have kept their OssDsign price target steady at SEK 12.75, indicating only marginal tweaks in the discount rate, long term revenue growth, profit margin and future P/E assumptions, rather than any major shift in their view of the company. What's in the News OssDsign issued earnings guidance for the first quarter of 2026, focusing on loss before interest and taxes rather than revenue or profit metrics.Anlatı Güncellemesi • Apr 04
OSSD: Stable Profitability Assumptions Will Support Future Multiple Re rating
Analysts keep their SEK 12.75 price target on OssDsign unchanged, citing steady assumptions around growth, margins, and a future P/E near 113x as the basis for maintaining the current valuation. Valuation Changes Fair Value: SEK 12.75 remains unchanged, so the target valuation level is consistent with prior assumptions.Anlatı Güncellemesi • Mar 20
OSSD: Stable Assumptions Will Support Long Term Margin Expansion
Analysts have maintained their SEK 12.75 price target for OssDsign, citing stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E as the basis for this unchanged view. Valuation Changes Fair Value: SEK 12.75 remains unchanged, signalling a stable central valuation estimate.Anlatı Güncellemesi • Mar 05
OSSD: New US Leadership Will Support Long Term Margin Expansion
Analysts have kept their OssDsign price target steady at SEK 12.75, citing largely unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for maintaining their view. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following his senior roles at Smith & Nephew plc, Medtronic Sofamor Danek Inc, and Medacta USA (Key Developments).Anlatı Güncellemesi • Feb 19
OSSD: New US-Focused Leadership Will Support Long Term Margin Expansion
Analysts are maintaining their SEK 12.75 price target on OssDsign. They point to a slightly higher discount rate, broadly similar revenue growth assumptions at around 26%, a lower profit margin outlook, and a higher future P/E expectation as key inputs behind this unchanged view.Anlatı Güncellemesi • Feb 04
OSSD: US Leadership Change Will Support Long Term Margin Expansion
Analysts have reduced their price target on OssDsign to €12.75 from €15.50, citing updated assumptions for growth, margins, and a lower future P/E multiple. What's in the News OssDsign AB appointed Mark Waugh as CEO, with his tenure set to begin on January 1, 2026, following a leadership transition from current CEO Morten Henneveld (Key Developments).Anlatı Güncellemesi • Jan 20
OSSD: New US Based Leadership Will Drive Future Orthobiologics Expansion
Analysts have kept their price target for OssDsign steady at €13.50, citing only marginal adjustments to the discount rate, revenue growth, profit margin and forward P/E assumptions that together are not enough to shift their overall valuation view. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following his senior roles at Smith & Nephew, Medtronic Sofamor Danek, and Medacta USA (company announcement).Anlatı Güncellemesi • Jan 06
OSSD: New US Focused Leadership Will Shape Bullish Future Outlook
Analysts have adjusted their price target on OssDsign to $13.50, reflecting updated assumptions around revenue growth, profit margin and a much higher implied future P/E multiple, while keeping their fair value estimate unchanged at $13.50. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following five years of leadership under outgoing CEO Morten Henneveld (Key Developments).Anlatı Güncellemesi • Dec 13
OSSD: New Leadership And Index Inclusion Will Shape Balanced Future Outlook
The analyst price target for OssDsign has been raised from SEK 12.0 to SEK 13.5, as analysts factor in a higher long term valuation multiple despite slightly slower projected revenue growth and a softer profit margin profile. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, succeeding Morten Henneveld after five years of leading the company through growth and transformation (company announcement) New CEO Mark Waugh brings over 20 years of international leadership experience across major orthopedic segments in the USA and Europe, including senior roles at Smith & Nephew, Medtronic Sofamor Danek, and Medacta USA (company announcement) OssDsign Catalyst driven orthobiologics focus has supported strong double digit growth in the U.S. market since its launch in August 2021 (company announcement) OssDsign AB (publ) has been added to the S&P Global BMI Index, increasing its visibility to international institutional investors (index provider) Valuation Changes Fair Value: Raised from SEK 12.0 to SEK 13.5, reflecting a modest upward revision in the company’s long term valuation.Anlatı Güncellemesi • Aug 08
Pure Play Orthobiologics Will Expand US Healthcare Access
With OssDsign's consensus price target revised lower, primarily driven by a notable drop in its Future P/E from 77.22x to 64.47x, the fair value estimate has decreased from SEK15.67 to SEK14.83. What's in the News An undisclosed buyer acquired an unknown minority stake in OssDsign AB from Karolinska Development AB.Analiz Makalesi • May 08
Optimistic Investors Push OssDsign AB (publ) (STO:OSSD) Shares Up 31% But Growth Is Lacking
OssDsign AB (publ) ( STO:OSSD ) shareholders would be excited to see that the share price has had a great month...
Yeni Anlatı • Apr 07
Pure Play Orthobiologics Will Expand US Healthcare Access
Strategic shift to orthobiologics boosts growth and operational efficiency, enhancing future revenue and sustaining high net margins.Analiz Makalesi • Feb 21
OssDsign AB (publ)'s (STO:OSSD) 25% Price Boost Is Out Of Tune With Revenues
OssDsign AB (publ) ( STO:OSSD ) shares have continued their recent momentum with a 25% gain in the last month alone...Analiz Makalesi • Feb 07
Analysts Are Upgrading OssDsign AB (publ) (STO:OSSD) After Its Latest Results
OssDsign AB (publ) ( STO:OSSD ) defied analyst predictions to release its full-year results, which were ahead of market...Analiz Makalesi • Nov 15
OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price
OssDsign AB (publ) ( STO:OSSD ) just released its latest quarterly results and things are looking bullish. OssDsign...Analiz Makalesi • Nov 13
OssDsign AB (publ)'s (STO:OSSD) Share Price Matching Investor Opinion
OssDsign AB (publ)'s ( STO:OSSD ) price-to-sales (or "P/S") ratio of 5.7x might make it look like a sell right now...Analiz Makalesi • Aug 23
OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price
Last week, you might have seen that OssDsign AB (publ) ( STO:OSSD ) released its quarterly result to the market. The...Analiz Makalesi • Aug 06
We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analiz Makalesi • Jun 19
Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now
Key Insights OssDsign's Annual General Meeting to take place on 25th of June CEO Morten Henneveld's total compensation...Analiz Makalesi • Mar 19
Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely
OssDsign AB (publ)'s ( STO:OSSD ) price-to-sales (or "P/S") ratio of 8.5x might make it look like a strong sell right...Hissedar Getirileri
| OSSD | SE Medical Equipment | SE Pazar | |
|---|---|---|---|
| 7D | 0% | -1.8% | 0.4% |
| 1Y | -67.8% | -7.0% | 15.1% |
Getiri vs. Endüstri: OSSD geçen yıl % -7 oranında getiri sağlayan Swedish Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: OSSD geçen yıl % 15.1 oranında getiri sağlayan Swedish Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| OSSD volatility | |
|---|---|
| OSSD Average Weekly Movement | 15.0% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.9% |
| 10% least volatile stocks in SE Market | 3.5% |
İstikrarlı Hisse Senedi Fiyatı: OSSD hisse senedi fiyatı, son 3 ayda Swedish piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: OSSD 'nin haftalık oynaklığı ( 15% ) geçen yıl boyunca sabit kaldı, ancak hala Swedish hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2011 | 35 | Mark Waugh | www.ossdsign.com |
OssDsign AB (publ) İsveç, Almanya, Amerika Birleşik Devletleri, Birleşik Krallık, Avrupa'nın geri kalanı ve uluslararası alanda kemik rejenerasyonu için implantlar ve malzeme teknolojisi tasarlar, üretir ve satar. Spinal füzyonlarda kemik büyümesini uyarmaya yardımcı olmak için kullanılan nanosentetik bir kemik grefti olan OssDsign Catalyst'i sunmaktadır. Şirket 2011 yılında kurulmuştur ve merkezi İsveç'in Uppsala kentindedir.
OssDsign AB (publ) Temel Bilgiler Özeti
| OSSD temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | SEK 457.99m |
| Kazançlar(TTM) | -SEK 47.88m |
| Gelir(TTM) | SEK 172.55m |
2.7x
P/S Oranı-9.6x
F/K OranıOSSD aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| OSSD gelir tablosu (TTM) | |
|---|---|
| Gelir | SEK 172.55m |
| Gelir Maliyeti | SEK 8.18m |
| Brüt Kâr | SEK 164.37m |
| Diğer Giderler | SEK 212.25m |
| Kazançlar | -SEK 47.88m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 18, 2026
| Hisse başına kazanç (EPS) | -0.43 |
| Brüt Marj | 95.26% |
| Net Kâr Marjı | -27.75% |
| Borç/Özkaynak Oranı | 0% |
OSSD uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/20 19:54 |
| Gün Sonu Hisse Fiyatı | 2026/06/18 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
OssDsign AB (publ) 3 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | ABG Sundal Collier |
| null null | ABG Sundal Collier Sponsored |
| Kristofer Liljeberg-Svensson | DNB Carnegie Commissioned Research |